JPH0487425A
(ja)
*
|
1990-07-31 |
1992-03-19 |
Fujitsu Ltd |
回線切り替え装置
|
US6414002B1
(en)
*
|
1999-09-22 |
2002-07-02 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
|
US6395767B2
(en)
*
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US6573287B2
(en)
*
|
2001-04-12 |
2003-06-03 |
Bristo-Myers Squibb Company |
2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
|
US7183290B2
(en)
*
|
2001-06-27 |
2007-02-27 |
Smithkline Beecham Corporation |
Fluoropyrrolidines as dipeptidyl peptidase inhibitors
|
DE60223920T2
(de)
*
|
2001-06-27 |
2008-11-13 |
Smithkline Beecham Corp. |
Pyrrolidine als dipeptidyl-peptidase-inhibitoren
|
HUP0400321A2
(hu)
*
|
2001-06-27 |
2004-08-30 |
Smithkline Beecham Corp. |
Fluorpirrolidin-származékok mint dipeptidil-dipeptidáz inhibitorok és ezeket tartalmazó gyógyszerkészítmények
|
AU2002348276A1
(en)
*
|
2001-11-16 |
2003-06-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US7772433B2
(en)
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
GB0205165D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205166D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205176D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205170D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205175D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
GB0205162D0
(en)
|
2002-03-06 |
2002-04-17 |
Astrazeneca Ab |
Chemical compounds
|
US20040014681A1
(en)
*
|
2002-05-14 |
2004-01-22 |
Ralph Ryback |
Method for treating dermatoses and tissue damage
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7378385B2
(en)
*
|
2002-08-08 |
2008-05-27 |
University Of Cincinnati |
Role for GLP-1 to mediate responses to disparate stressors
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7238724B2
(en)
*
|
2002-09-19 |
2007-07-03 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
US7262207B2
(en)
*
|
2002-09-19 |
2007-08-28 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
US20040121964A1
(en)
*
|
2002-09-19 |
2004-06-24 |
Madar David J. |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
US7632858B2
(en)
*
|
2002-11-15 |
2009-12-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
US8309603B2
(en)
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US7420079B2
(en)
|
2002-12-09 |
2008-09-02 |
Bristol-Myers Squibb Company |
Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
|
US20060052382A1
(en)
*
|
2002-12-20 |
2006-03-09 |
Duffy Joseph L |
3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
|
EP1608317B1
(fr)
*
|
2003-03-25 |
2012-09-26 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
US7371871B2
(en)
|
2003-05-05 |
2008-05-13 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase
|
CN101837127A
(zh)
|
2003-05-05 |
2010-09-22 |
前体生物药物股份公司 |
谷氨酰胺酰基和谷氨酸环化酶效应物的应用
|
PL1620082T3
(pl)
|
2003-05-05 |
2010-10-29 |
Probiodrug Ag |
Medyczne zastosowanie inhibitorów cyklazy glutaminylowej i glutaminianowej do leczenia choroby Alzheimera i zespołu Downa
|
US7638638B2
(en)
|
2003-05-14 |
2009-12-29 |
Takeda San Diego, Inc. |
Dipeptidyl peptidase inhibitors
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6995183B2
(en)
*
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7169926B1
(en)
|
2003-08-13 |
2007-01-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7678909B1
(en)
|
2003-08-13 |
2010-03-16 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7470700B2
(en)
*
|
2003-08-13 |
2008-12-30 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US7205409B2
(en)
*
|
2003-09-04 |
2007-04-17 |
Abbott Laboratories |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
WO2005030751A2
(fr)
*
|
2003-09-08 |
2005-04-07 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de dipeptidyle peptidase
|
JP2007505121A
(ja)
*
|
2003-09-08 |
2007-03-08 |
武田薬品工業株式会社 |
ジペプチジルぺプチダーゼ阻害剤
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
CN102302781A
(zh)
|
2003-10-15 |
2012-01-04 |
前体生物药物股份公司 |
谷氨酰胺酰基环化酶效应物和谷氨酸环化酶效应物的应用
|
CA2544573A1
(fr)
|
2003-11-03 |
2005-06-02 |
Probiodrug Ag |
Combinaisons utiles au traitement de troubles neuronaux
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
ES2524916T3
(es)
*
|
2003-11-12 |
2014-12-15 |
Sino-Med International Alliance, Inc. |
Compuestos heterocíclicos de ácido borónico
|
US20070149451A1
(en)
*
|
2003-11-17 |
2007-06-28 |
Holmes David G |
Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
|
CN1905876B
(zh)
|
2003-11-17 |
2010-06-09 |
诺瓦提斯公司 |
二肽基肽酶iv抑制剂的用途
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP1715893B8
(fr)
|
2004-01-20 |
2009-12-16 |
Novartis Ag |
Formulation a compression directe et procede correspondant
|
US7470810B2
(en)
|
2004-01-21 |
2008-12-30 |
Bristol-Myers Squibb Company |
Alkyl and aryl-thiotrifluoroacetates and process
|
WO2005073186A1
(fr)
*
|
2004-01-29 |
2005-08-11 |
Ono Pharmaceutical Co., Ltd. |
Dérivés de pyrrolidine
|
EP1712547B1
(fr)
*
|
2004-02-05 |
2011-12-14 |
Kyorin Pharmaceutical Co., Ltd. |
Derive de bicycloester
|
CA2554809C
(fr)
|
2004-02-05 |
2014-04-29 |
Probiodrug Ag |
Nouveaux inhibiteurs de la glutaminyl-cyclase comportant de la n thiouree alkyle et de l'imidazolyl substitue par thioamide
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005077900A1
(fr)
*
|
2004-02-18 |
2005-08-25 |
Kyorin Pharmaceutical Co., Ltd. |
Dérivés d'amides bicycliques
|
US20070238753A1
(en)
*
|
2004-02-27 |
2007-10-11 |
Madar David J |
Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
|
EP1719757B1
(fr)
*
|
2004-02-27 |
2013-10-09 |
Kyorin Pharmaceutical Co., Ltd. |
Derive bicyclo
|
US7732446B1
(en)
|
2004-03-11 |
2010-06-08 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
AU2004318013B8
(en)
*
|
2004-03-15 |
2011-10-06 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
TW200534879A
(en)
*
|
2004-03-25 |
2005-11-01 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
TW200538122A
(en)
|
2004-03-31 |
2005-12-01 |
Bristol Myers Squibb Co |
Process for preparing a dipeptidyl peptidase Ⅳ inhibitor and intermediates employed therein
|
US7741082B2
(en)
*
|
2004-04-14 |
2010-06-22 |
Bristol-Myers Squibb Company |
Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
|
US20050256314A1
(en)
*
|
2004-05-04 |
2005-11-17 |
Soojin Kim |
Process employing controlled crystallization in forming crystals of a pharmaceutical
|
TW200536827A
(en)
*
|
2004-05-04 |
2005-11-16 |
Bristol Myers Squibb Co |
Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
|
US7829720B2
(en)
*
|
2004-05-04 |
2010-11-09 |
Bristol-Myers Squibb Company |
Process for preparing atazanavir bisulfate and novel forms
|
US7214702B2
(en)
*
|
2004-05-25 |
2007-05-08 |
Bristol-Myers Squibb Company |
Process for producing a dipeptidyl peptidase IV inhibitor
|
TWI354569B
(en)
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
JP2008501714A
(ja)
*
|
2004-06-04 |
2008-01-24 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼインヒビター
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
WO2006019965A2
(fr)
|
2004-07-16 |
2006-02-23 |
Takeda San Diego, Inc. |
Inhibiteurs de la dipeptidyl peptidase
|
AU2005267093B2
(en)
*
|
2004-07-23 |
2009-10-01 |
Nuada Llc |
Peptidase inhibitors
|
TW200608967A
(en)
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
US20060035954A1
(en)
*
|
2004-08-11 |
2006-02-16 |
Sharma Padam N |
Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP2008524331A
(ja)
|
2004-12-21 |
2008-07-10 |
武田薬品工業株式会社 |
ジペプチジルペプチダーゼ阻害剤
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
DOP2006000008A
(es)
*
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
JP2008024592A
(ja)
*
|
2005-01-28 |
2008-02-07 |
Taisho Pharmaceut Co Ltd |
シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
|
WO2006086464A2
(fr)
*
|
2005-02-10 |
2006-08-17 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones utilisees comme modulateurs de la 5ht
|
JP2008115080A
(ja)
*
|
2005-04-22 |
2008-05-22 |
Taisho Pharmaceutical Co Ltd |
併用医薬
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20060264433A1
(en)
*
|
2005-05-23 |
2006-11-23 |
Backes Bradley J |
Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
CN101268075A
(zh)
*
|
2005-07-28 |
2008-09-17 |
百时美施贵宝公司 |
作为5-羟色胺受体激动剂和拮抗剂的取代的四氢-1h吡啶并[4,3,b]吲哚
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
TW200738245A
(en)
*
|
2005-08-22 |
2007-10-16 |
Sankyo Co |
Pharmaceutical composition containing FBPase inhibitor
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
ES2453981T3
(es)
|
2005-08-31 |
2014-04-09 |
University Of Tennessee Research Foundation |
Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM)
|
PE20070622A1
(es)
*
|
2005-09-14 |
2007-08-22 |
Takeda Pharmaceutical |
Administracion de inhibidores de dipeptidil peptidasa
|
CA2622472C
(fr)
*
|
2005-09-14 |
2013-11-19 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase permettant de traiter le diabete
|
US20070060528A1
(en)
*
|
2005-09-14 |
2007-03-15 |
Christopher Ronald J |
Administration of dipeptidyl peptidase inhibitors
|
CN101360723A
(zh)
*
|
2005-09-16 |
2009-02-04 |
武田药品工业株式会社 |
制备嘧啶二酮衍生物的方法
|
TW200745079A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
TW200745080A
(en)
*
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
EP1971614A1
(fr)
|
2005-11-14 |
2008-09-24 |
Probiodrug AG |
Derives de pyrrolidine a fusion de cyclopropyle, en tant qu'inhibiteurs de dipeptidyle peptidase iv (dp iv)
|
GB0526291D0
(en)
*
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
EP1995237A4
(fr)
*
|
2006-03-08 |
2011-07-06 |
Kyorin Seiyaku Kk |
Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production
|
RU2465264C2
(ru)
*
|
2006-03-16 |
2012-10-27 |
Вертекс Фармасьютикалз Инкорпорейтед |
Дейтерированные ингибиторы протеазы гепатита с
|
WO2007112368A1
(fr)
*
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Préparation de dichlorhydrate de (r)-3-aminopipéridine
|
WO2007112347A1
(fr)
|
2006-03-28 |
2007-10-04 |
Takeda Pharmaceutical Company Limited |
Inhibiteurs de la dipeptidyl peptidase
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
DK1971862T3
(da)
*
|
2006-04-11 |
2011-02-14 |
Arena Pharm Inc |
Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
|
PE20071221A1
(es)
*
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
EA200802054A1
(ru)
|
2006-04-12 |
2009-04-28 |
Пробиодруг Аг |
Ингибиторы фермента
|
EP2014648A4
(fr)
*
|
2006-04-17 |
2010-10-13 |
Sumitomo Chemical Co |
Procédé de production d'un dérivé de proline polycyclique ou d'un sel d'adduit acide
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2873524C
(fr)
|
2006-05-04 |
2018-02-20 |
Boehringer Ingelheim International Gmbh |
Une forme polymerique de 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
EP1852108A1
(fr)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Compositions d'inhibiteurs de la DPP IV
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
JP5215300B2
(ja)
|
2006-07-12 |
2013-06-19 |
ユニバーシティ オブ テネシー リサーチ ファウンデーション |
置換アシルアニリドおよびそれらの使用方法
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
WO2008028914A1
(fr)
|
2006-09-07 |
2008-03-13 |
Nycomed Gmbh |
Polythérapie contre le diabète sucré
|
AU2007296556B2
(en)
*
|
2006-09-13 |
2013-09-19 |
Takeda Pharmaceutical Company Limited |
Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
|
PE20080840A1
(es)
*
|
2006-09-13 |
2008-08-27 |
Smithkline Beecham Corp |
Metodos para administrar agentes hipoglucemiantes de larga duracion
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
EP2063905B1
(fr)
|
2006-09-18 |
2014-07-30 |
Raptor Pharmaceutical Inc |
Traitement des troubles hépatiques par l'administration de conjugués de protéine associée au récepteur (rap)
|
WO2008055945A1
(fr)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
|
US8217025B2
(en)
*
|
2006-11-17 |
2012-07-10 |
Harbor Therapeutics, Inc. |
Drug screening and treatment methods
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
SI2091948T1
(sl)
|
2006-11-30 |
2012-07-31 |
Probiodrug Ag |
Novi inhibitorji glutaminil ciklaze
|
US9604931B2
(en)
|
2007-01-22 |
2017-03-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
WO2008091555A2
(fr)
|
2007-01-22 |
2008-07-31 |
Gtx, Inc. |
Agents se liant aux récepteurs nucléaires
|
US9623021B2
(en)
|
2007-01-22 |
2017-04-18 |
Gtx, Inc. |
Nuclear receptor binding agents
|
CN101230058A
(zh)
*
|
2007-01-23 |
2008-07-30 |
上海恒瑞医药有限公司 |
双环氮杂烷类衍生物、其制备方法及其在医药上的用途
|
BRPI0807453B8
(pt)
|
2007-02-01 |
2021-05-25 |
Takeda Pharmaceuticals Co |
preparação sólida
|
WO2008098256A1
(fr)
*
|
2007-02-09 |
2008-08-14 |
Bristol-Myers Squibb Company |
Procédés pour l'identification de patients ayant une forte probabilité de réagir aux inhibiteurs de dpp-iv
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
US20080064701A1
(en)
*
|
2007-04-24 |
2008-03-13 |
Ramesh Sesha |
Anti-diabetic combinations
|
US8143427B2
(en)
*
|
2007-03-22 |
2012-03-27 |
Kyorin Pharmaceutical Co., Ltd. |
Method for producing aminoacetylpyrrolidinecarbonitrile derivative
|
TW200904405A
(en)
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Pharmaceutical formulations containing an SGLT2 inhibitor
|
ES2529149T3
(es)
|
2007-04-03 |
2015-02-17 |
Mitsubishi Tanabe Pharma Corporation |
Una combinación de inhibidor de dipeptidil peptidasa IV y edulcorante para uso en el tratamiento de la obesidad
|
EP2142514B1
(fr)
|
2007-04-18 |
2014-12-24 |
Probiodrug AG |
Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CN101754972A
(zh)
*
|
2007-05-18 |
2010-06-23 |
百时美施贵宝公司 |
Sglt2抑制剂的晶体结构及其制备方法
|
CN101318925A
(zh)
*
|
2007-06-04 |
2008-12-10 |
上海恒瑞医药有限公司 |
吡咯烷并四元环类衍生物、其制备方法及其在医药上的用途
|
EP2152663B1
(fr)
|
2007-06-04 |
2014-03-19 |
Ben Gurion University of the Negev Research and Development Authority |
Composés triarylés et compositions les comprenant
|
AU2008268627A1
(en)
*
|
2007-06-22 |
2008-12-31 |
Bristol-Myers Squibb Company |
Tableted compositions containing atazanavir
|
AU2008268630A1
(en)
*
|
2007-06-22 |
2008-12-31 |
Bristol-Myers Squibb Company |
Tableted compositions containing atazanavir
|
DE602008005896D1
(de)
*
|
2007-06-22 |
2011-05-12 |
Bristol Myers Squibb Co |
Tablettierte atazanavirhaltige zusammensetzungen
|
US20100183715A1
(en)
*
|
2007-06-22 |
2010-07-22 |
Bristo-Meyers Squibb Company |
Tableted compositions containing atazanavir
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
ES2733348T3
(es)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
US20090076118A1
(en)
*
|
2007-09-13 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched saxagliptin
|
US8338450B2
(en)
*
|
2007-09-21 |
2012-12-25 |
Lupin Limited |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
US8551524B2
(en)
*
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2108960A1
(fr)
|
2008-04-07 |
2009-10-14 |
Arena Pharmaceuticals, Inc. |
Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
|
WO2009140685A2
(fr)
*
|
2008-05-16 |
2009-11-19 |
Bristol-Myers Squibb Company |
Procédés d'identification de sujets à forte probabilité de réaction à des inhibiteurs de dpp-iv
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
US8003689B2
(en)
|
2008-06-20 |
2011-08-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
WO2010016584A1
(fr)
*
|
2008-08-07 |
2010-02-11 |
杏林製薬株式会社 |
Procédé de fabrication d'un dérivé de bicyclo[2.2.2]octylamine
|
US20110190322A1
(en)
|
2008-08-14 |
2011-08-04 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
CA2733778A1
(fr)
*
|
2008-08-14 |
2010-02-18 |
Hiroshi Uchida |
Composition pharmaceutique stabilisee
|
CN102149407A
(zh)
|
2008-09-10 |
2011-08-10 |
贝林格尔.英格海姆国际有限公司 |
治疗糖尿病和相关病症的组合疗法
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
CA2740685C
(fr)
|
2008-10-17 |
2018-09-11 |
Sanofi-Aventis Deutschland Gmbh |
Combinaison d'une insuline et d'un agoniste de glp-1
|
EP2344519B1
(fr)
|
2008-11-07 |
2016-09-28 |
The General Hospital Corporation |
Fragments c-terminaux du peptide 1 de type glucagon (glp-1)
|
EP2352722A4
(fr)
*
|
2008-11-19 |
2012-07-25 |
Auspex Pharmaceuticals Inc |
Inhibiteurs à base d hydroxyadamantyle de dipeptidylpeptidase iv
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
DE102008062136B4
(de)
|
2008-12-16 |
2012-05-03 |
Kamamed Ug |
Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch
|
BRPI0923121A2
(pt)
|
2008-12-23 |
2015-08-11 |
Boehringer Ingelheim Int |
Formas salinas de compostos orgânico
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
US8706650B2
(en)
*
|
2009-01-14 |
2014-04-22 |
Integral Analytics, Inc. |
Optimization of microgrid energy use and distribution
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
CN102307577A
(zh)
|
2009-02-13 |
2012-01-04 |
贝林格尔.英格海姆国际有限公司 |
包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途
|
AU2010212823B2
(en)
|
2009-02-13 |
2016-01-28 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
BRPI1013500A2
(pt)
*
|
2009-03-27 |
2016-04-05 |
Astrazeneca Uk Ltd |
métodos para previnir eventos cardiovasculares adversos maiores com inibidores de dpp-iv
|
JPWO2010110436A1
(ja)
|
2009-03-27 |
2012-10-04 |
杏林製薬株式会社 |
塩基性添加剤を含有するマトリックス型徐放性製剤
|
EP2417260A1
(fr)
*
|
2009-04-08 |
2012-02-15 |
Bristol-Myers Squibb Company |
Plasmide génétiquement stable exprimant les enzymes pdh et fdh
|
JP6088245B2
(ja)
*
|
2009-04-09 |
2017-03-01 |
サンド・アクチエンゲゼルシヤフト |
サクサグリプチンの結晶形態
|
WO2010146597A1
(fr)
|
2009-06-18 |
2010-12-23 |
Lupin Limited |
Dérivés de 2-amino-2-[8-(diméthylcarbamoyl)-8-aza-bicyclo[3.2.1]oct-3-yl]-exo-éthanoyle comme puissants inhibiteurs de la dpp-iv
|
AR077642A1
(es)
|
2009-07-09 |
2011-09-14 |
Arena Pharm Inc |
Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
|
ES2548913T3
(es)
|
2009-09-11 |
2015-10-21 |
Probiodrug Ag |
Derivados heterocíclicos como inhibidores de glutaminil ciclasa
|
EP2308847B1
(fr)
|
2009-10-09 |
2014-04-02 |
EMC microcollections GmbH |
Pyridines substituées servant d'inhibiteurs de dipeptidyl-peptidase IV et leurs application pour le traitement du diabète et des maladies associées
|
JP5973918B2
(ja)
*
|
2009-11-13 |
2016-08-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Glp−1アゴニスト及びメチオニンを含む薬学的組成物
|
AU2010317995B2
(en)
|
2009-11-13 |
2014-04-17 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
|
JP5784623B2
(ja)
|
2009-11-13 |
2015-09-24 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
速放性錠剤製剤
|
ES2689107T3
(es)
|
2009-11-13 |
2018-11-08 |
Astrazeneca Ab |
Formulaciones de tabletas bicapa
|
CN102753161A
(zh)
|
2009-11-27 |
2012-10-24 |
贝林格尔.英格海姆国际有限公司 |
基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
JP6026284B2
(ja)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤
|
JP5688745B2
(ja)
|
2010-03-10 |
2015-03-25 |
プロビオドルグ エージー |
グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
|
US20130109703A1
(en)
|
2010-03-18 |
2013-05-02 |
Boehringer Ingelheim International Gmbh |
Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
|
EP2368874A1
(fr)
|
2010-03-26 |
2011-09-28 |
Sandoz AG |
Racémisation de (R)-N-Boc-3-hydroxyadamant-1-yl glycine
|
CA2795514A1
(fr)
*
|
2010-04-05 |
2011-10-13 |
Cadila Pharmaceuticals Limited |
Nouveaux composes hypoglycemiques
|
JP2013523819A
(ja)
|
2010-04-06 |
2013-06-17 |
アリーナ ファーマシューティカルズ, インコーポレイテッド |
Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
|
WO2011131748A2
(fr)
|
2010-04-21 |
2011-10-27 |
Probiodrug Ag |
Nouveaux inhibiteurs
|
WO2011138421A1
(fr)
|
2010-05-05 |
2011-11-10 |
Boehringer Ingelheim International Gmbh |
Combinaison thérapeutique
|
KR20130038258A
(ko)
|
2010-05-05 |
2013-04-17 |
아시아 케미컬 인더스트리스 리미티드 |
삭사글립틴 중간체, 삭사글립틴 다형 및 이들의 제조 방법
|
EP3124041A1
(fr)
|
2010-06-24 |
2017-02-01 |
Boehringer Ingelheim International GmbH |
Traitement du diabète
|
EP2601175A1
(fr)
|
2010-08-06 |
2013-06-12 |
Sandoz AG |
Nouveau composé cristallin comprenant de la saxagliptine et de l'acide phosphorique
|
EP2601176A1
(fr)
|
2010-08-06 |
2013-06-12 |
Sandoz AG |
Nouveaux sels de saxagliptine comportant des diacides organiques
|
JP6199186B2
(ja)
|
2010-08-30 |
2017-09-20 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
2型糖尿病の治療用の医薬の製造のためのave0010の使用
|
EP2611770A1
(fr)
|
2010-09-03 |
2013-07-10 |
Sandoz AG |
Procédé d'amination réductrice d'acides -céto-carboxyliques
|
AU2011295837B2
(en)
|
2010-09-03 |
2015-06-18 |
Astrazeneca Uk Limited |
Drug formulations using water soluble antioxidants
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
KR101871011B1
(ko)
|
2010-09-22 |
2018-06-25 |
아레나 파마슈티칼스, 인크. |
Gpr119 수용체의 조절제 및 그와 관련된 장애의 치료
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
EP2608788A1
(fr)
|
2010-10-04 |
2013-07-03 |
Assia Chemical Industries Ltd. |
Polymorphes de chlorhydrate de saxagliptine et leurs procédés de préparation
|
US9040481B2
(en)
|
2010-11-02 |
2015-05-26 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
SG191772A1
(en)
|
2011-01-31 |
2013-08-30 |
Cadila Healthcare Ltd |
Treatment for lipodystrophy
|
WO2012106303A1
(fr)
|
2011-02-01 |
2012-08-09 |
Bristol-Myers Squibb Company |
Formulations pharmaceutiques comprenant un composé amine
|
WO2012123563A1
(fr)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase
|
WO2012135570A1
(fr)
|
2011-04-01 |
2012-10-04 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
|
WO2012145361A1
(fr)
|
2011-04-19 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
US20140038889A1
(en)
|
2011-04-22 |
2014-02-06 |
Arena Pharmaceuticals, Inc. |
Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
|
WO2012145604A1
(fr)
|
2011-04-22 |
2012-10-26 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
WO2012170702A1
(fr)
|
2011-06-08 |
2012-12-13 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
|
EP2729157B1
(fr)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
Un pentapeptide dérivé de l'extrémité c-terminale du glp-1 (glucagon-like peptide 1) pour le traitement
|
ES2713566T3
(es)
|
2011-07-15 |
2019-05-22 |
Boehringer Ingelheim Int |
Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
|
RU2650616C2
(ru)
|
2011-08-29 |
2018-04-16 |
Санофи-Авентис Дойчланд Гмбх |
Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
WO2013036213A1
(fr)
|
2011-09-07 |
2013-03-14 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Formulations d'inhibiteur de dpp-iv
|
PL2578208T3
(pl)
|
2011-10-06 |
2014-10-31 |
Sanovel Ilac Sanayi Ve Ticaret As |
Stałe formulacje dawkowane inhibitora DPP-IV
|
WO2013055910A1
(fr)
|
2011-10-12 |
2013-04-18 |
Arena Pharmaceuticals, Inc. |
Modulateurs du récepteur gpr119 et traitement de troubles associés
|
JPWO2013081100A1
(ja)
*
|
2011-11-30 |
2015-04-27 |
積水メディカル株式会社 |
アダマンチルヒダントイン化合物
|
US9115082B2
(en)
|
2012-01-18 |
2015-08-25 |
Catherine Yang |
Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US20150087686A1
(en)
|
2012-04-25 |
2015-03-26 |
Enantia, S.L. |
Crystalline forms of saxagliptin
|
WO2013171167A1
(fr)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
|
US8664443B2
(en)
|
2012-05-23 |
2014-03-04 |
Divi's Laboratories Ltd. |
Process for the preparation of (1S, 3S, 5S)-2-[2(S)-2-amino-2-(3-hydroxy-1-adamantan-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbonitrile
|
CA2885957C
(fr)
|
2012-05-24 |
2019-10-22 |
Apotex Pharmachem India Pvt. Ltd |
Sels de saxagliptine avec des acides organiques
|
WO2013174767A1
(fr)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
|
WO2014006569A2
(fr)
|
2012-07-02 |
2014-01-09 |
Ranbaxy Laboratories Limited |
Sels de saxagliptine
|
CN103539724B
(zh)
*
|
2012-07-12 |
2017-09-26 |
博瑞生物医药(苏州)股份有限公司 |
沙格列汀单一立体异构体的新晶型和纯化方法
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
CN104754939A
(zh)
|
2012-07-13 |
2015-07-01 |
Gtx公司 |
用选择性雄激素受体调节剂(sarm)治疗雄激素受体(ar)阳性乳癌的方法
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
WO2014030051A1
(fr)
|
2012-08-23 |
2014-02-27 |
Aurobindo Pharma Limited |
Compositions pharmaceutiques stables comprenant de la saxagliptine
|
WO2014057495A1
(fr)
|
2012-10-11 |
2014-04-17 |
Lee Pharma Limited |
Procédé de préparation industrielle de la [(s)-n-tert butoxycarbonyl-3-hydroxy]adamantylglycine
|
TWI500613B
(zh)
|
2012-10-17 |
2015-09-21 |
Cadila Healthcare Ltd |
新穎之雜環化合物
|
WO2014074668A1
(fr)
|
2012-11-08 |
2014-05-15 |
Arena Pharmaceuticals, Inc. |
Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
|
DK2925735T3
(da)
|
2012-11-20 |
2019-06-17 |
Lexicon Pharmaceuticals Inc |
Inhibitorer for natriumglucose-cotransporter 1
|
WO2014096982A1
(fr)
|
2012-12-21 |
2014-06-26 |
Wockhardt Limited |
Compositions pharmaceutiques stables de saxagliptine ou des sels de celle-ci
|
WO2014096983A1
(fr)
|
2012-12-21 |
2014-06-26 |
Wockhardt Limited |
Compositions pharmaceutiques stables de saxagliptin ou des sels de celui-ci
|
WO2014108830A1
(fr)
|
2013-01-10 |
2014-07-17 |
Wockhardt Limited |
Procédé pour la préparation de sel pharmaceutiquement acceptable de saxagliptine
|
ITMI20130132A1
(it)
|
2013-01-30 |
2014-07-31 |
Laboratorio Chimico Int Spa |
Procedimento per la preparazione di intermedi di sintesi di saxagliptina e nuovi composti
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
CN104059068B
(zh)
*
|
2013-03-20 |
2017-02-08 |
中国科学院上海药物研究所 |
β‑氨基羰基类化合物、其制备方法、药物组合物及其用途
|
CN104098481B
(zh)
*
|
2013-04-10 |
2016-05-11 |
浙江九洲药物科技有限公司 |
一种沙格列汀中间体的制备方法
|
AU2013387996B2
(en)
|
2013-04-22 |
2015-12-10 |
Cadila Healthcare Limited |
A novel composition for nonalcoholic fatty liver disease (NAFLD)
|
WO2014193528A1
(fr)
*
|
2013-04-29 |
2014-12-04 |
Anovel Pharmaceuticals, Llc |
Préparations amorphes et méthodes associées
|
US20160107989A1
(en)
|
2013-05-30 |
2016-04-21 |
Cadila Healthcare Limited |
A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
|
KR102272746B1
(ko)
|
2013-06-05 |
2021-07-08 |
보슈 헬스 아일랜드 리미티드 |
구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
IN2013MU02470A
(fr)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
EP2832723B1
(fr)
|
2013-07-29 |
2017-02-15 |
Zentiva, a.s. |
Formes amorphes stabilisées de la Saxagliptine
|
US9416105B2
(en)
|
2013-08-28 |
2016-08-16 |
Amneal Pharmaceuticals Llc |
Process for preparation of saxagliptin and its hydrochloride salt
|
IN2013MU02905A
(fr)
|
2013-09-06 |
2015-07-03 |
Cadila Healthcare Ltd |
|
ITMI20131677A1
(it)
*
|
2013-10-10 |
2015-04-11 |
Olon Spa |
Procedimento per la preparazione di saxagliptina
|
EA201690938A1
(ru)
|
2013-11-05 |
2016-11-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Соединения для лечения диабета и осложнений, возникающих из-за этого заболевания
|
WO2015067223A1
(fr)
|
2013-11-06 |
2015-05-14 |
Zentiva, K., S. |
Sel de l-tartrate de (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile et procédé de préparation
|
WO2015071889A1
(fr)
|
2013-11-18 |
2015-05-21 |
Ranbaxy Laboratories Limited |
Compositions orales de saxagliptine
|
WO2015071887A1
(fr)
|
2013-11-18 |
2015-05-21 |
Ranbaxy Laboratories Limited |
Compositions pharmaceutiques orales de saxagliptine
|
WO2015087262A1
(fr)
|
2013-12-11 |
2015-06-18 |
Ranbaxy Laboratories Limited |
Procédé pour la préparation de saxagliptine et de ses intermédiaires
|
JP6723921B2
(ja)
|
2014-01-09 |
2020-07-15 |
サノフイSanofi |
インスリンアナログおよび/またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
MX2016008979A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
|
ES2950384T3
(es)
|
2014-02-28 |
2023-10-09 |
Boehringer Ingelheim Int |
Uso médico de un inhibidor de DPP-4
|
CZ2014177A3
(cs)
*
|
2014-03-24 |
2015-10-07 |
Zentiva, K.S. |
Způsob výroby saxagliptinu
|
EP3148587B1
(fr)
|
2014-05-30 |
2021-02-24 |
Pfizer Inc |
Dérivés carbonitriles en tant que modulateurs sélectifs du récepteur des androgènes
|
WO2016016770A1
(fr)
|
2014-07-26 |
2016-02-04 |
Wockhardt Limited |
Nouvelle composition pharmaceutique à libération modifiée de la sitagliptine ou d'un sel pharmaceutiquement acceptable correspondant
|
GB201415598D0
(en)
|
2014-09-03 |
2014-10-15 |
Univ Birmingham |
Elavated Itercranial Pressure Treatment
|
CN104557667A
(zh)
*
|
2014-12-12 |
2015-04-29 |
山东省药学科学院 |
2-氰基吡咯烷类化合物、制备方法及其应用
|
HRP20230470T1
(hr)
|
2014-12-12 |
2023-07-21 |
Sanofi-Aventis Deutschland Gmbh |
Formulacija fiksnog omjera inzulin glargin/liksisenatid
|
CA2979033A1
(fr)
|
2015-03-09 |
2016-09-15 |
Intekrin Therapeutics, Inc. |
Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
CN105037245B
(zh)
*
|
2015-08-03 |
2017-04-12 |
沧州那瑞化学科技有限公司 |
一种沙格列汀中间体的制备方法
|
US10385017B2
(en)
|
2015-10-14 |
2019-08-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
KR101715682B1
(ko)
|
2015-10-29 |
2017-03-13 |
경동제약 주식회사 |
삭사글립틴의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 삭사글립틴의 제조방법
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
BR112019011740A2
(pt)
|
2016-12-09 |
2019-10-29 |
Cadila Healthcare Ltd |
composição farmacêutica e método para o tratamento de colangite biliar primária
|
WO2018162722A1
(fr)
|
2017-03-09 |
2018-09-13 |
Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke |
Inhibiteurs de dpp-4 à utiliser dans le traitement de fractures osseuses
|
US11253508B2
(en)
|
2017-04-03 |
2022-02-22 |
Coherus Biosciences, Inc. |
PPARy agonist for treatment of progressive supranuclear palsy
|
EP3461819B1
(fr)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibiteurs de la glutaminyl-cyclase
|
CN109970620B
(zh)
*
|
2017-12-27 |
2022-07-12 |
江苏威凯尔医药科技有限公司 |
一种制备沙格列汀中间体的方法
|
WO2019241574A1
(fr)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Procédés pour abaisser la glycémie avec une composition pharmaceutique d'inhibiteur de la dipeptidylpeptidase-4
|
CA3105626A1
(fr)
|
2018-07-19 |
2020-01-23 |
Astrazeneca Ab |
Methodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
EP3856714A1
(fr)
|
2018-09-26 |
2021-08-04 |
Lexicon Pharmaceuticals, Inc. |
Formes cristallines de n-(1 -((2-(diméthylamino)éthyl)amino)-2-m éthyl-1 -oopropan-2-yl)-4-(4-(2-méthyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(méthylthio)tétrahydro-2h-pyran-2-yl)benzyl) phényl)butanamide et procédés de synthèse associés
|
RU2712097C1
(ru)
*
|
2018-09-28 |
2020-01-24 |
Общество с ограниченной ответственностью "Необиотек" |
Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа, соединения (варианты)
|
RU2727898C1
(ru)
*
|
2020-02-25 |
2020-07-24 |
Общество с ограниченной ответственностью «Необиотек» |
Фармацевтическая композиция на основе действующего вещества, ингибитора дипептидилпептидазы-4, для предупреждения развития и лечения сахарного диабета 2 типа
|
WO2022022865A1
(fr)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Procédés de traitement d'une maladie rénale chronique avec de la dapagliflozine
|
WO2023275715A1
(fr)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Métabolites de modulateurs sélectifs du récepteur des androgènes
|
CN113666846B
(zh)
*
|
2021-08-31 |
2023-06-27 |
济南立德医药技术有限公司 |
沙格列汀中间体的合成方法
|
WO2023144722A1
(fr)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozine destinée à être utilisée dans le traitement du prédiabète ou pour réduire le risque de développer un diabète de type 2
|